PRM — Big Pharma Split Balance Sheet
0.000.00%
Last trade - 00:00- CA$17.37m
- -CA$13.86m
- CA$5.78m
Annual balance sheet for Big Pharma Split, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 36.7 | 24.5 | 25.7 | 26.2 | 31.2 |
| Net Total Receivables | 1.07 | 14.5 | 0.795 | 0.097 | 0.619 |
| Total Current Assets | 37.8 | 39.1 | 26.5 | 26.3 | 31.8 |
| Total Assets | 37.8 | 39.1 | 26.5 | 26.3 | 31.8 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.548 | 9.51 | 0.386 | 1.05 | 0.404 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.548 | 9.51 | 0.386 | 1.05 | 0.404 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Total Equity | 37.3 | 29.6 | 26.1 | 25.3 | 31.4 |
| Total Liabilities & Shareholders' Equity | 37.8 | 39.1 | 26.5 | 26.3 | 31.8 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |